Horizon Pharma Downgraded to “Neutral” at Zacks (HZNP)
Horizon Pharma (NASDAQ:HZNP) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a note issued to investors on Wednesday, AnalystRatingsNetwork reports. They currently have a $10.60 target price on the stock. Zacks‘ price objective would suggest a potential upside of 6.75% from the stock’s previous close.
Other equities research analysts have also recently issued reports about the stock. Analysts at JMP Securities raised their price target on shares of Horizon Pharma from $10.00 to $16.00 in a research note to investors on Thursday, January 30th. They now have an “outperform” rating on the stock. Separately, analysts at R. F. Lafferty raised their price target on shares of Horizon Pharma from $9.00 to $11.00 in a research note to investors on Wednesday, January 29th. They now have a “buy” rating on the stock. Finally, analysts at Piper Jaffray reiterated a “buy” rating on shares of Horizon Pharma in a research note to investors on Wednesday, November 20th. They now have a $7.00 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $10.77.
Shares of Horizon Pharma (NASDAQ:HZNP) traded down 0.30% during mid-day trading on Wednesday, hitting $9.90. 988,493 shares of the company’s stock traded hands. Horizon Pharma has a 1-year low of $1.97 and a 1-year high of $10.68. The stock’s 50-day moving average is $8.29 and its 200-day moving average is $4.96. The company’s market cap is $652.0 million.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Friday, November 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.22. The company had revenue of $31.50 million for the quarter, compared to the consensus estimate of $18.31 million. During the same quarter in the previous year, the company posted ($0.47) earnings per share. On average, analysts predict that Horizon Pharma will post $-0.82 earnings per share for the current fiscal year.
Horizon Pharma, Inc operates as a biopharmaceutical company. It is focused on developing and commercializing medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.